Immunexpress To Present SeptiCyte RAPID Comparative Data Against Lactate And Procalcitonin For Diagnosing Sepsis At IDWeek 2021

Immunexpress, Inc., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, announced a presentation demonstrating comparative data of SeptiCyte RAPID, lactate, and procalcitonin in differentiating sepsis from infection negative systemic inflammation at IDWeek 2021, taking place virtually on Sept. 29 – Oct. 3, 2021.

Recommended AI News: Fintica AI Completes Financial Market Manipulation Detection Pilot For Israel Securities Authority

Details of the presentations are as follows:
Abstract ID: 994
Title: Comparison of lactate, procalcitonin and a gene signature assay alone or in combination to differentiate sepsis from infection negative systematic inflammation in ICU patients.
Presenter: Erkan Hassan, Pharm. D., Chief Clinical Officer, Sepsis Program Optimization, Clarksville, Maryland, United States
Session Details: B1. Studies of correlates of protection (or biomarkers) against microbial infection and disease in patients or experimental models

The abstract is published in the Conference Interactive Program Planner page. The poster and accompanying audio will be accessible during the Conference to registered attendees, who can also talk via live video chat with the authors of the study at the Immunexpress virtual exhibit. The poster will also be available on the Clinical Publications page of the Technology section of the company’s product website at www.septicyte.com.

Recommended AI News: Zype Acquires MAZ Systems to Extend Leading Video API and Infrastructure Platform with No-Code TV…